Effects of Preactivated MC540 in the Treatment of Lymphocytic Plasmacytic Stomatitis in Feline Leukemia virus and Feline Immunodeficiency virus Positive Cats
Restricted accessResearch articleFirst published online March, 1993
Effects of Preactivated MC540 in the Treatment of Lymphocytic Plasmacytic Stomatitis in Feline Leukemia virus and Feline Immunodeficiency virus Positive Cats
Photoactive compounds and drugs are used therapeutically as antibacterial, antiviral and antitumor agents. This report examines the use of a photoactive compound, preactivated merocyanine 540 (pMC540), in the treatment of stomatitis in two cats that are both feline immunodeficiency virus (FIV) positive. One of the cats was also feline leukemia virus (FeLV) positive. Dramatic short term improvement is reported with the dosage regimen and complications.
Get full access to this article
View all access options for this article.
References
1.
ScatchardG.The attractions of protein for small molecules and ions.Ann NY Acad Sci1949; 51: 660–672.
2.
HamerF.M.The cyanine dyes and related compounds.New York: Wiley Interscience, 1964; 706–742.
3.
FooteC.S.Photosensitized oxidation and singlet oxygen: Consequences in biological systems. In: PryorW.A., ed. Free Radicals in Biology.New York: Academic Press,1976; 2: 86–133.
4.
WallisC., MelnickJ.L.Photodynamic in-activation of animal viruses: a review.Photochem Photobiol1966; 4: 159–170.
5.
DavilaJ., GulliyaK.S., HarrimanA.Inactivation of tumors and viruses via efficient photoimerisation.J Chem Soc Commun1989; 1215–1216.
6.
GollnickK.Chemical aspects of photodynamic action in the presence of molecular oxygen. In: NygaardO.F., AdlerH.I., SinclairW.K., eds. 5th International Congress of Radiation Research, Seattle, Washington.New York: Academic Press, 1975; 590–611.
7.
SpikesI.D.Photobiology of porphyrins.Prog Clin Biol Res1984; 170: 19–39.
8.
GulliyaK.S., MatthewsI.L.Photosensitization of leukemic cells and normal bone marrow cells by 514 nm laser light and effects of laser light on migration inhibition and lymphokine response.Cell Biol Int Rept1988; 12: 305–312.
9.
GulliyaK.S., MatthewsJ.L., FayI.W., DowbenR.M.Increased survival of normal cells during laser photodynamic therapy: implications for ex vivo autologous bone marrow purging.Life Sci1988; 42: 2651–2656.
10.
GulliyaK.S., PervaizS.Elimination of clonogenic tumor cells from HL-60, Daudi, and U-937 cell lines by laser photoradiation therapy: implications for autologous bone marrow purging.Blood1989; 43: 1059–1065.
11.
MatthewsJ.L., Sogandares-BernalF., JudyM.Photodynamic inactivation of human immunodeficiency virus in human blood.
DoughertyT.J.An overview of the status of photoradiation therapy. In: DorironD.R., GomerC.I., eds. Porphyrin Localization and Treatment of Tumors.New York: Liss,1984; 170: 75–87.
14.
AtzpodienJ., GulatiS.C., ClarksonB.D.Comparison of the cytotoxic effects of merocyanine-540 on leukemic cells and normal human bone marrow.Cancer Res,1986; 46: 4892–4895.
15.
GulliyaK.S., PervaizS., DowbenR.M., MatthewsJ.L.Tumor cell specific cytotoxicity of light-exposed merocyanine 540: implications for systemic therapy without light.Photochem Photobiol1990; 52(4): 831–838.
16.
GulliyaK.S., ChanhT., NewmanI., PervaizS., MatthewsJ.L.Preactivation a novel antitumor and antiviral approach.1990; 26(5): 551–553.
17.
DavilaI., HarrimanA., GulliyaK.S.Photochemistry of merocyanine 540: the mechanism of chemotherapeutic activity with cyanine dyes.1991; 53(1): 1–11.
18.
ChanhT.C., AllanJ.S., PervaizS., MatthewsJ.L., TrevinoS.R., GulliyaK.S.Preactivated merocyanine 540 inactivates HIV-1 and SIV: Potential therapeutic and blood banking applications.J Acquired Immune Deficiency Syndromes, New York: Raven Press,1992; 5: 188–195.
19.
PervaizS., HarrimanA., GulliyaK.S.Protein damage by photoproducts of merocyanine 540.Free Radical Biology and Medicine,1992; 12: 389–396.
20.
PervaizS., BattaglinoM., MatthewsJ.L., GulliyaK.S.Biodistribution and toxicity of photoproducts of merocyanine 540.Cancer Chemother Pharmacol1993; 31: 1–8.
21.
SpencerL.World AIDS Day 1992 - how veterinarians are helping.I Am Vet Med Assoc1992; 201(11): 1663.
22.
SpencerL.Pets prove therapeutic for people with AIDS.I Am Vet Med Assoc1992; 201(11): 1665–1668.
23.
SpencerL.Study explores health risks and the human/animal bond.I Am Vet Med Assoc1992; 201(11): 1669.
24.
ZuziakP.Nonhuman primates hold clues to search for AIDS vaccine.I Am Vet Med Assoc1992; 201(11): 1670–1671.
25.
SpencerL.Immunologic response to EIAV offers hope for AIDS treatment.J Am Vet Med Assoc1992; 201(11): 1672–1673.
26.
KramM., SpencerL.Encountering AIDS - a personal perspective.I Am Vet Med Assoc1992; 201(11): 1667.
27.
KahlerS.Immunodeficiency syndrome makes cats desirable HIV model.I Am Vet Med Assoc1992; 201(11): 1674–1675.
FlemingE.J., McCawD.L., SmithI.A.Clinical, hematologic and survival data from cats infected with feline immunodeficiency virus: 42 cases (1983–1988).I Am Vet Med Assoc1991; 199(7): 913–916.
30.
EgberinkH.F., HartmanK., HorzinekM.C.Chemotherapy of feline immunodeficiency virus infection.Am I Vet Res1992; 199: 1485–1487.
31.
LafradoU., MathesL.E., ZachP.M.Biological effects of staphylococcal protein A immunotherapy in cats with induced feline leukemia virus infection.Am J Vet Res1990; 51: 482–486.
32.
SheetsM.A., UngerB.A., GigglemanG.F.Jr.Studies of the effect of acemannan on retrovirus infections: clinical stabilization of feline leukemia virus-infected cats.Mol Biother1991; 3: 41–45.
33.
WolfA.M.Feline Leukemia Virus An Update, TNAVC 1993 Proceedings, 255–257.
